Tiel

This study evaluates the long-term safety and tolerability of pelacarsen TQJ230 in people with established cardiovascular disease and elevated Lipoproteina who completed a previous related study. It is an open-label extension trial, meaning all participants receive the study drug without placebo comparison. The trial is sponsored by Novartis Pharmaceuticals and focuses on continued treatment after the completion of the parent study. Participants receive monthly injections of pelacarsen 80 mg subcutaneously for up to 36 months during this extension phase. This phase is designed to provide access to the study drug after the initial trial and to monitor participants closely. The study does not involve randomization or blinding, and all enrolled participants receive the active drug. During the study, participants will undergo regular assessments including monitoring for adverse events and cardiovascular events, as well as measuring Lipoproteina levels at baseline and several time points over 36 months. Safety and tolerability will be closely tracked throughout the treatment period. The total duration of participation corresponds to the length of the extension phase, up to three years.

This trial evaluates different doses of the drug AP31969 to control the rhythm of atrial fibrillation AF and to determine its safety. The study is a randomized Phase 2 trial comparing AP31969 to a placebo in adults diagnosed with paroxysmal or persistent AF who have a measurable AF burden. The study aims to reduce AF burden and improve quality of life using oral medication. Participants are assigned randomly to receive one of several doses of AP31969 100 mg, 200 mg, 350 mg, or later 500 mg or a placebo. All treatments are given as tablets taken orally twice daily for 12 weeks. The study includes three periods screening up to 4 weeks, treatment 12 weeks, and a follow-up period of 30 days. Participants will have an implantable loop recorder to monitor heart rhythm continuously. During the study, participants will attend scheduled visits where blood and urine tests, electrocardiograms, and other assessments will be performed. Researchers will track AF burden, the number of AF episodes, quality of life changes, and episodes of ventricular tachycardia. The total participation time is about 20 weeks, including all study periods, with safety and treatment effects monitored carefully.

Researchers are studying maridebart cafraglutide to evaluate its effect on reducing cardiovascular problems and death in people with atherosclerotic cardiovascular disease who are also overweight or obese. This Phase 3 trial compares maridebart cafraglutide to a placebo, both given alongside standard care, to see if maridebart cafraglutide works better in lowering heart-related risks. Participants will receive either maridebart cafraglutide or a placebo, both administered by subcutaneous injection. The study lasts for up to approximately 35 months, during which researchers monitor several heart and health outcomes. These include heart attacks, strokes, death rates, hospitalizations, blood pressure, body measurements, blood sugar control, cholesterol levels, kidney function, and inflammatory markers. During the trial, participants will have regular assessments including physical exams, blood tests, and monitoring of heart events. Researchers track the time to first major heart-related events and changes in health markers over the study period. Safety is also monitored by recording any adverse events. The total participation time can last nearly three years, allowing careful observation of the effects of the study drug compared to placebo.

This research focuses on patients with acute coronary syndrome ACS, a leading cause of death worldwide. It aims to create an ongoing registry to evaluate the long-term effects of diagnostics, treatments, and devices used for ACS in real-world clinical practice. The study addresses gaps left by traditional randomized controlled trials by capturing data from routine care and broader patient populations to improve cardiovascular care and quality of life. The study uses a nonrandomized observational design to collect detailed clinical and possibly genetic information from patients with ACS. This registry allows evaluation of various therapies, devices, and diagnostic tools used in daily practice. It also examines follow-up care pathways, risk score usage for medication duration, and adherence to treatment guidelines, aiming to enhance personalized medicine and secondary prevention. Participants provide information during routine clinical visits, with data collected prospectively and followed over time. Researchers monitor outcomes such as mortality, recurrent ischemic events, hospital admissions, and quality of life. The main measure is the number of participants tracked at three years. This long-term observation helps evaluate the effectiveness and safety of treatments in everyday clinical settings and supports ongoing improvements in ACS care.

Researchers are evaluating the effectiveness of two different doses of Atropine eye drops 0.05% and 0.5% in slowing the progression of axial length growth in European children aged 6 to 11 years with progressive myopia. The study aims to compare how well these doses prevent worsening of myopia, assess safety, adherence to treatment, and reasons why some children might not respond to the treatment. Progressive myopia can lead to serious eye problems, so preventing its advancement in childhood is important to reduce risks of vision loss later in life. Participants in this study will be randomly assigned to receive either Atropine 0.05% or Atropine 0.5% eye drops. They will administer one drop in each eye once daily at bedtime for 3 years. After this treatment phase, participants will be observed for an additional 2 years without treatment to monitor long-term effects. This design helps compare the two doses in terms of controlling eye growth and side effects over time. During the study, children will have their eye measurements taken to track axial length progression, visual function tests, and assessments of their response to treatment and any side effects. Researchers will also monitor adherence to the eye drop regimen and evaluate quality of life changes over 5 years. The primary outcome is the change in axial length after 3 years of treatment, with additional follow-up to 5 years. Safety and vision tests will be performed regularly to ensure participant well-being throughout the trial.

Researchers are investigating how various factors beyond tumor stage, such as biochemical, histopathological, genomic, environmental, and clinical characteristics, affect the outcomes of patients diagnosed with colorectal cancer CRC, small bowel cancer, and anal cancer. This observational study aims to collect detailed information from diagnosis through long-term follow-up to better understand prognosis and treatment effects in both early and late-stage cancers. The study addresses the gap between clinical trial populations and real-world patients by including a broader patient group treated in general practice. Participants will be followed prospectively from their initial diagnosis until death. Data collection includes medical history, clinical parameters, imaging, pathology, tumor details, treatments, hospital stays, interventions, and adverse events. With separate consent, patient-reported quality of life and work ability information will also be gathered. Additionally, biological samples obtained during routine care may be collected for further observational and molecular research. This cohort serves as a platform for evaluating new interventions through a Trials within Cohorts TwiCs design. Throughout up to ten years of follow-up, participants will undergo assessments of progression-free survival, disease-free survival, overall survival, and serious adverse events. Quality of life and work ability are assessed at intervals of 3, 6, 12, 24, 36, and 48 months. This extensive data collection supports a wide range of research aims including prognostic studies, molecular analyses, comparisons of new treatments, and health policy evaluations. The study provides a comprehensive view of treatment outcomes and patient experiences in everyday clinical settings.